Martin Brenner is CEO and CSO of iBio. IBio uses its AI drug discovery platform to tackle complex and challenging drug targets with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise. Martin is a seasoned executive and drug hunter with a unique journey spanning electrical engineering to veterinary medicine to scientific leadership roles.
He has led drug discovery teams at several top global pharma companies, including Eli Lilly, Pfizer, AstraZeneca, and Merck. Prior to his current role at iBio, Martin was VP and head of R&D at Stoke Therapeutics, CSO at Recursion, and CSO at Phoenix, which was eventually acquired by Ligon Pharmaceuticals.
Get the latest from The Biotech Startups Podcast delivered straight to your inbox. Subscribe for weekly updates on new episodes—featuring expert insights, actionable advice, and stories from across the biotech industry.
